相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015
Susan Jin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Off-label drug use in oncology: a systematic review of literature
M. M. Saiyed et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
PRIME time at the EMA
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2017)
Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015
Nicholas S. Downing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou et al.
JCO PRECISION ONCOLOGY (2017)
Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine
Apostolia-Maria Tsimberidou
CURRENT PROBLEMS IN CANCER (2017)
Going social to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access
Tim K. Mackey et al.
BMC MEDICINE (2016)
BRAF-Directed Therapy in Metastatic Colorectal Cancer
Krittiya Korphaisarn et al.
CANCER JOURNAL (2016)
Equal access to innovative therapies and precision cancer care
Agnes Buzyn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period
Jonathan P. Jarow et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2016)
Access to Investigational Drugs: FDA Expanded Access Programs or Right-to-Try Legislation?
M. E. Blair Holbein et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2015)
Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The US Food and Drug Administration-European Medicines Agency Collaboration in Pharmacovigilance: Common Objectives and Common Challenges
Gerald J. Dal Pan et al.
DRUG SAFETY (2015)
Proposal for Patient Obligations for Access to Unapproved Medical Interventions: Both Too Much and Not Enough
Audrey Chapman
AMERICAN JOURNAL OF BIOETHICS (2014)
Ethical Justifications for Access to Unapproved Medical Interventions: An Argument for (Limited) Patient Obligations
Mary Jean Walker et al.
AMERICAN JOURNAL OF BIOETHICS (2014)
Compassion and Research in Compassionate Use
David Magnus
AMERICAN JOURNAL OF BIOETHICS (2014)
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2014)
Assessing decision-making capacity at end of life
Elissa Kolva et al.
GENERAL HOSPITAL PSYCHIATRY (2014)
Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration
Robert E. Martell et al.
ONCOLOGIST (2013)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
Regulatory Review of Novel Therapeutics - Comparison of Three Regulatory Agencies
Nicholas S. Downing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009
K. I. Kaitin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
Francesco Trotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Accelerated Approval and Oncology Drug Development Timelines
Michael L. Lanthier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program
John F. Scoggins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
Elizabeth A. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Role of Investigational Therapy in Management of Patients With Advanced Metastatic Malignancy
Emil J. Freireich et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Right to Experimental Treatment: FDA New Drug Approval, Constitutional Rights, and the Public's Health
Elizabeth Weeks Leonard
JOURNAL OF LAW MEDICINE & ETHICS (2009)
Expanded access rules pose quandary for drug developers
George S. Mack et al.
NATURE BIOTECHNOLOGY (2009)
Access to Experimental Drugs for Terminally Ill Patients
Benjamin P. Falit et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Patients and medical statistics - Interest, confidence, and ability
S Woloshin et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2005)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
